GPR30 CRISPR Activation Plasmid (h): sc-402502-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GPR30 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GPR30 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GPR30 CRISPR Activation Plasmid (h) and GPR30 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GPER1 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPR30 CRISPR Activation Plasmid (h) | sc-402502-ACT | 20 µg | $397.00 | |||
GPR30 CRISPR Activation Plasmid (h2) | sc-402502-ACT-2 | 20 µg | $397.00 |
GPER1 encodes GPR30 (GPER), a membrane-associated estrogen receptor that mediates rapid, non-genomic estrogen signaling and integrates with canonical estrogen-responsive transcriptional programs. GPR30 activation can engage cAMP/PKA, EGFR transactivation, MAPK/ERK, PI3K/AKT, and intracellular Ca²⁺ flux, influencing proliferation, migration, metabolism, and inflammatory signaling in a cell-type-dependent manner. Dysregulated GPER1/GPR30 signaling has been implicated in hormone-responsive cancers, cardiovascular and metabolic dysfunction, and neuroinflammatory processes, making it a useful node for dissecting estrogen-driven pathway crosstalk. As a biomarker-linked signaling receptor, GPR30 is frequently studied for its impact on cell-state transitions, receptor trafficking, and stress-response gene networks.
GPR30 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GPER1 expression without altering the underlying DNA sequence.
GPR30 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GPER1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GPER1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GPR30 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GPER1 locus and enabling the study of GPR30-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GPR30 pathway restoration in tumor cells with silenced or reduced GPER1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.